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Swertia chirayita (Gentianaceae), a popular medicinal herb indigenous to the temperate
Himalayas is used in traditional medicine to treat numerous ailments such as
liver disorders, malaria, and diabetes and are reported to have a wide spectrum
of pharmacological properties. Its medicinal usage is well-documented in Indian
pharmaceutical codex, the British, and the American pharmacopeias and in different
traditional medicine such as the Ayurveda, Unani, Siddha, and other conventional
medical systems. This ethnomedicinal herb is known mostly for its bitter taste caused by
the presence of different bioactive compounds that are directly associated with human
health welfare. The increasing high usage of Swertia chirayita, mostly the underground
tissues, as well as the illegal overharvesting combined with habitat destruction resulted
in a drastic reduction of its populations and has brought this plant to the verge of
extinction. The increasing national and international demand for Swertia chirayita has
led to unscrupulous collection from the wild and adulteration of supplies. The aim of
this review is to provide a synthesis of the current state of scientific knowledge on the
medicinal uses, phytochemistry, pharmacological activities, safety evaluation as well as
the potential role of plant biotechnology in the conservation of Swertia chirayita and
to highlight its future prospects. Pharmacological data reported in literature suggest
that Swertia chirayita shows a beneficial effect in the treatment of several ailments.
However, there is lack of adequate information on the safety evaluation of the plant.
The pharmacological usefulness of Swertia chirayita requires the need for conservation-
friendly approaches in its utilization. Providing high-quality genetically uniform clones
for sustainable use and thereby saving the genetic diversity of this species in nature is
important. In this regard, plant biotechnological applications such as micropropagation,
synthetic seed production, and hairy root technology can play a significant role in a holistic
conservation strategy. In addition to micropropagation, storage of these valuable genetic
resources is equally important for germplasm preservation. However, more advanced
research is warranted to determine the activities of bioactive compounds in vitro and
in vivo, establish their underlying mechanisms of action and commence the process of
clinical research.
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INTRODUCTION
One of the prerequisites for the success of primary health care is
the availability and use of suitable drugs. Traditional medicine is
still the most affordable and easily accessible source of treatment
in the primary healthcare system. Medicinal plants have always
been a potential source to cure different diseases, either in the
form of traditional preparations or as pure active principles, and
they are frequently the only source of medicine for the majority
of people in the developing world.
Swertia, a genus in the family Gentianaceae include a large
group of annual and perennial herbs, representing approximately
135 species. Swertia species are common ingredients in a number
of herbal remedies. In India, 40 species of Swertia are recorded
(Clarke, 1885; Kirtikar and Basu, 1984), of which, Swertia
chirayita is considered the most important for its medicinal
properties. S. chirayita was first described by Roxburgh under
the name of Gentiana chyrayta in 1814 (Scartezzini and Speroni,
2000). S. chirayita, common name: “Chiretta” (Figure 1) is a
critically endangered medicinal herb that grows at high altitudes
in the sub-temperate regions of the Himalayas between 1200 and
2100m altitudes from Kashmir to Bhutan (Bentley and Trimen,
1880; Clarke, 1885) on the slopes of moist shady places (Gaur,
1999; Figure 2). Its widespread uses in traditional medicine have
resulted in over-exploitation from the natural habitat and it is
Abbreviations: ABTS, 2,2-azino-bis (3-ethylebenzothiazoline-6-sulphonic acid);
ACE, Acetone; BA, 6-benzyl-adenine; BHA, Butylated hydroxy anisole; BHT,
Butylated hydroxytoluene; 2,4-D, 2,4-Dicholorophenoxyacetic acid; DPPH, 2,2-
diphenyl-1-picrylhydrazyl; DW, Dry weight; EtOH, Ethanol; EA, Ethyl acetate;
FRAP, Ferric Reducing Antioxidant Power; GA3, Gibberellic acid; HEX, Hexane;
IAA, Indole-3-acetic acid; KN, Kinetin; MeOH, Methanol; NAA, Naphthalene
Acetic Acid; PE, Petroleum ether.
FIGURE 1 | Swertia chirayita. (A) Seeds, (B) Plant in nature, (C) Root of a mature plant, (D) Dry plant material, (E) High shoot multiplication in a plant tissue culture
system.
now on the verge of extinction in the wild. S. chirayita is also
known by an array of names such as Anaryatikta, Bhunimba,
Chiratitka, Kairata in Sanskrit, Qasabuzzarirah in Arab and
Farsi, Chiaravata in Urdu, Sekhagi in Burma, and Chirrato or
Chiraita in Nepal (Joshi and Dhawan, 2005). Some authors have
described S. chirayita as an annual (Anon, 1982; Kirtikar and
Basu, 1984) and others as a biennial or pluri-annual (Edwards,
1993). This ethnomedicinal herb is known mostly for its bitter
taste caused by the presence of different chemical constituents
such as amarogentin (most bitter compound isolated till date),
swerchirin, swertiamarin, and other bioactive compounds that
are directly associated with human health welfare (Joshi and
Dhawan, 2005). Due to its excessive over-exploitation from
the natural habitat, narrow geographic occurrence (Bhat et al.,
2013) and unresolved inherent problems of seed viability and
seed germination (Badola and Pal, 2002; Joshi and Dhawan,
2005), alternative approaches for propagation and conservation
are urgently required to avoid the possible extinction of this
important species. Consequently, S. chirayita has been receiving
increasing attention from a wide range of researchers as evident
from the number of publications appearing in the literature
(Chen et al., 2011; Nagalekshmi et al., 2011; Ghosh et al.,
2012; Kumar and Chandra, 2013, 2014, 2015; Fan et al., 2014;
Kumar et al., 2014; Sharma et al., 2014, 2015; Padhan et al.,
2015; Zhou et al., 2015). However, a comprehensive review
detailing the documented ethnomedicinal uses, pharmacological
properties and safety evaluation carried out on S. chirayita
and identifying the existing knowledge gap is lacking. In this
review, we document the medicinal uses and phytochemical
properties of S. chirayita. Future prospects including the potential
conservation approaches to ensure a continuous supply for
both local and international expanding markets and safety
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FIGURE 2 | Natural distribution of Swertia chirayita. The shaded area represents the natural habitat of Swertia chirayita in the Himalayan Region.
evaluation on uses of the species for medicinal purposes are
highlighted.
Botanical Description
S. chirayita is an annual/biennial herb 0.6–1.5m tall. It has an
erect, around 2–3 ft long stem, the middle portion is cylindrical,
while the upper is quadrangular, with a prominent decurrent
line at each angle. Its stem is orange brown or purplish in color
with large continuous yellowish pith (Bentley and Trimen, 1880;
Joshi and Dhawan, 2005). Leaves are lanceolate, in opposite
pairs, no stalks, acuminate, cordate at the base, sessile, five to
seven nerved and 4 cm long (Scartezzini and Speroni, 2000).
The root is simple, yellowish, somewhat oblique, or geniculate,
tapering and short, almost 7–8 cm long and usually half an
inch thick (Bentley and Trimen, 1880; Scartezzini and Speroni,
2000). Flowers are small, numerous, tetramerous, large leafy
panicles, green-yellow, and tinged with purple and green or
white hairs (Scartezzini and Speroni, 2000; Joshi and Dhawan,
2005). The calyx is gamophyllous with four lobes, corolla-lobes
four twisted and superimposed, united at the base where they
have pairs of nectaries on each lobe covered with long hairs.
Stamens 4, opposite the corolla lobe, at the base of the corolla.
Ovary unilocular with ovules laminal placentation parietale; two
stigmas. Capsules are egg-shaped, 2-valved with a transparent
yellowish pericarp. Seeds are numerous, very small and dark
brownish in color (Chandra et al., 2012). Multi-colored corolla
and the presence of nectaries support cross-pollination in S.
chirayita.
MEDICINAL USES
S. chirayita a traditional Ayurvedic herb is used by different
indigenous population groups in multiple ways for several
medicinal purposes (Table 1). The whole plant is widely used
by local people for the treatment of hepatitis, inflammation,
and digestive diseases (Bhatt et al., 2006). The wide range
of medicinal uses include the treatment of chronic fever,
malaria, anemia, bronchial asthma, hepatotoxic disorders,
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TABLE 1 | Ethnobotanical uses of Swertia chirayita in traditional medicine.
Plant part
used
Traditional uses References
Whole plant Used in several traditional and indigenous systems of medicines, such as
Ayurveda, Unani, and Siddha
Mukherji, 1953; Kirtikar and Basu, 1984; Joshi and Dhawan, 2005;
Whole plant Used in British and American pharmacopeias as tinctures and infusions Joshi and Dhawan, 2005
Root Serves as a drug and an effective tonic for general weakness, fever, cough, joint
pain, asthma, and the common cold
Kirtikar and Basu, 1984; Joshi and Dhawan, 2005
Whole plant For headaches and blood pressure, the leaves and chopped stems are soaked
overnight in water. A paste is prepared and filtered with 1 glass of water. The
preparation is consumed once a day for 2–3 days
de Rus Jacquet et al., 2014; Malla et al., 2015
Whole plant For Tremor fever, whole S. chirayita plants are cut into small pieces and boiled in
1/2 L of water until the volume is reduced to less than half glass. The filtered
water is stored in a glass bottle and half spoon is given to children once a day for
2 days. For adult, the posology is 1 spoon once in a day for 2 days and varies to
three times a day until cured
de Rus Jacquet et al., 2014
Whole plant Boiled in water and one cup of decoction is taken orally to cure malaria Shah et al., 2014
Whole plant Paste of the plant is applied to treat skin diseases such as eczema and pimples Joshi and Dhawan, 2005; Malla et al., 2015
Whole plant Liver disorders; stomach disorders like dyspepsia and diarrhea, intestinal worms Mukherji, 1953; Joshi and Dhawan, 2005
Whole plant Hiccups and vomiting, ulcers, gastrointestinal infections, and kidney diseases Kirtikar and Basu, 1984
Whole plant Used in combination with other drugs in cases of scorpion bite Nandkarni, 1976
Whole plant Used in excessive vaginal discharge Jadhav and Bhutani, 2005
liver disorders, hepatitis, gastritis, constipation, dyspepsia, skin
diseases, worms, epilepsy, ulcers, scanty urine, hypertension,
melancholia, and certain types of mental disorders, secretion
of bile, blood purification, and diabetes (Karan et al., 1999;
Banerjee et al., 2000; Rai et al., 2000; Saha et al., 2004;
Chen et al., 2011). Recently, S. chirayita extracts showed
anti-hepatitis B virus (anti-HBV) activities (Zhou et al.,
2015). Traditionally, decoctions of this species are used for
anthelmintic, hepatoprotective, hypoglycemic, antimalarial,
antifungal, antibacterial, cardiostimulant, antifatigue, anti-
inflammatory, antiaging, antidiarrheal, as protectant of the
heart and also help in lowering blood pressure and blood
sugar (Schimmer and Mauthner, 1996). Herbal formulations
such as Ayush-64, Diabecon, Mensturyl syrup, and Melicon
V ointment (Edwin and Chungath, 1988; Mitra et al., 1996)
contain S. chirayita extract in different concentrations for
its antipyretic, hypoglycaemic, antifungal, and antibacterial
properties. Furthermore, the curative value of this herb has also
been recorded in ancient Ayurveda medicine systems and other
conventional medical systems.
The widespread uses of S. chirayita in traditional drugs have
resulted in considerable chemical analysis of the plant, and active
principles which attribute the plant its medicinal properties. S.
chirayita is also used in British and American pharmacopeias as
tinctures and infusions (Joshi and Dhawan, 2005). The whole
plant is used in traditional remedies but the root is mentioned
to be the most bioactive part (Kirtikar and Basu, 1984).
PHARMACOLOGICAL ACTIVITY
The varied ethnobotanical uses of S. chirayita have led to the
initiation of various pharmacological investigations. Previous
research demonstrates that the S. chirayita extracts exhibit
a wide range of biological activities, such as antibacterial,
antifungal, antiviral, anticancer, anti-inflammatory, and others
like antidiabetic and antioxidant activities (Verma et al., 2008;
Alam et al., 2009; Arya et al., 2011; Chen et al., 2011; Laxmi et al.,
2011). Concurrently, a diverse range of in vitro and in vivo test
systems has been used to evaluate the pharmacological properties
of S. chirayita. Evidence-based laboratory investigations indicate
that aqueous, alcoholic and methanolic extracts of S. chirayita
possess a number of promising pharmacological properties. The
whole plant of S. chirayita have been reported to be used for the
treatment of antibacterial and antifungal activity (Alam et al.,
2009; Laxmi et al., 2011; Rehman et al., 2011). Anti-hepatitis
B virus activity of S. chirayita extracts was also studied on
HepG 2.2.15 cells line (Zhou et al., 2015). The whole plant of
S. chirayita has been reported for the anti-inflammatory and
hypoglycemic activity (Banerjee et al., 2000; Kar et al., 2003;
Alam et al., 2011; Das et al., 2012; Verma et al., 2013). Chen
et al. (2011) investigated the 70% ethanolic extract of S. chirayita
for antioxidant activities by using antioxidant tests including
reducing power and beta-carotene assay. The results showed that
70% ethanolic extracts exhibited high DPPH scavenging activity
(IC50 = 267.80µg/mL). Table 2 presents a summary focusing
on the pharmacological evaluations using in vitro and in vivo
systems whereas Table 3 provides antioxidant potential of S.
chirayita.
PHYTOCHEMISTRY
The widespread uses of S. chirayita as a traditional drug and its
commercialization in modern medical systems have led to a rise
in scientific exploration of its phytochemistry in order to identify
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TABLE 2 | Evaluation of the biological activities of Swertia chirayita.
Bioactivity
evaluated
Plant part(s)
tested
Test
system
aExtracting
solvent
Test Organism/Models Control Toxicity test References
Antibacterial Whole plant In vitro EtOH Escherichia coli ATCC 26922 Ciprofloxacin None Rehman et al., 2011
Klebsiella pneumonia ATCC
15380
Pseudomonas aeruginosa
ATCC 25619
Proteus vulgaris ATCC 6380
Antibacterial Stem In vitro MeOH Bacillus subtilis ATCC 6633 Ceftriaxone, Ceftriaxone
sodium, Cefuroxine,
Ciprofloxacin, Gentamycine,
Levofloxacin, Metronidazole,
Tranexamicacid
None Khalid et al., 2011
Enterococcus faecalis (ATCC
14506)
Staphylococcus aureus
(ATCC 6538)
Pseudomonas aeruginosa
(ATCC 27853)
Salmonella typhi (ATCC
14028)
Antibacterial Whole plant In vitro MeOH Bacillus subtilis MTCC 736 Gentamycin None Laxmi et al., 2011
Bacillus polymyxa
Staphylococcus aureus
MTCC 3160
Escherichia coli MTCC 723
Salmonella typhi MTCC 3216
Vibria cholera MTCC 3906
Streptococcus pyogenes
MTCC 1927
Proteus mirabilis MTCC 1429
Providentia alkalifaciens
Pseudomonas aeruginosa
MTCC 7837
Antibacterial Whole plant In vitro DCM; EtOH Staphylococcus aureus Kanamycin 30µg/disc None Alam et al., 2009
Antibacterial Stem In vitro EtOH Staphylococcus aureus Chloramphenicol 30µg/disc Brine shrimp
assay–positive
Sultana et al., 2007
Bacillus subtilis
Salmonella typhi
Shigella flexeneriae
Sarcina lutea
Bacillus megaterium
Antifungal Whole plant In vitro MeOH Aspegillus niger MTCC 1881 Amphotericin None Laxmi et al., 2011
Aspergillus flavus MTCC
1883
Cladosporium oxysporum
MTCC 1777
Antileishmanial Aerial part In vitro 95% EtOH Leishmania donovani UR6 – None Ray et al., 1996
Antileishmanial Whole plant In vitro MeOH Leishmania donovani AG83 – Cytotoxicity
test-negative
Medda et al., 1999
Antihelmintic Whole plant In vitro Water; MeOH Haemonchus contortus Levamisole 0.55mg/ml None Iqbal et al., 2006
Antimalarial Leaves/Stem In vitro MeOH; PE;
Water; EtOH
Plasmodium falciparum
FCK 2
Parasitized red blood cells
and 10 µCi of
[35S]-methionine
None Bhat and Surolia,
2001
(Continued)
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TABLE 2 | Continued
Bioactivity
evaluated
Plant part(s)
tested
Test
system
aExtracting
solvent
Test Organism/Models Control Toxicity test References
Egg hatchability
and larvicidal
Whole plant In vitro HEX; EA;
MeOH
Aedes aegypti Tween-80 None Balaraju et al.,
2009b
Culex quinquefasciatus
Anti-hepatitis B
virus
Whole plant In vitro 50% EtOH HepG 2.2.15 cells line Tenofovir None Zhou et al., 2015
Antiinflammatory Aerial parts In vivo Petroleum N/A Mice treated with vehicle or
Diclofenac (10mg/kg)
None Banerjee et al., 2000
Antiinflammatory Root In vivo 95% EtOH N/A Diclofenac (25mg/kg) None Das et al., 2012
Hypoglycemic Whole plant In vivo 95% EtOH N/A Mice treated with vehicle None Kar et al., 2003
Hypoglycemic Leaves In vivo EtOH N/A Glibenclamide (5mg/kg) None Alam et al., 2011
Hypoglycemic Whole plant In vivo EA; EtOH N/A Glibenclamide (5mg/kg) Cytotoxicity
test-negative
Verma et al., 2013
Antidiabetic Whole plant In vitro 95% EtOH;
HEX
STZ-NAD(streptozotocin-
nicotinamide) induced
diabetic albino mice
Metformin (100µg/kg) None Grover et al., 2002
Antidiabetic Whole plant In vitro EtOH; HEX;
Chloroform
STZ-NAD(streptozotocin-
nicotinamide) induced
diabetic albino mice
Metformin (100µg/kg) None Arya et al., 2011
Antipyretic Root In vitro Water Brewer’s yeast induced
pyrexia Typhoid-Paratyphoid
A, B vaccine induced
Hyperexia
Paracetamol (150mg kg−1) None Bhargava et al.,
2009
Anticarcinogenic Whole plant In vivo HEX N/A 9,10-dimethyl
benz(a)anthracene (DMBA)
None Saha et al., 2004
Analgesic Leaves/Stem In vivo EtOH N/A Diclofenac sodium
(25mg/kg)
None Alam et al., 2010
Analgesic Root In vivo EtOH N/A Aminopyrine (50mg/kg) None Das et al., 2012
Hepatoprotective Aerial parts In vivo 70% EtOH N/A Paracetamol (150mg/kg) None Nagalekshmi et al.,
2011
CNS Whole plant In vivo EtOH N/A Mice treated with vehicle None Bhattacharya et al.,
1976
Antiviral Leaves/Stem In vitro Water Herpes simplex virus type-1 Acyclovir (1 mg/mL) Cytotoxicity
test-negative
Verma et al., 2008
aExtracting solvent: EtOH, ethanol; EA, ethyl acetate; HEX, hexane; MeOH, methanol; N/A, not applicable; PE, petroleum ether.
the active phytochemicals. This has resulted in a considerable
body of literature exploring the chemical constituents of
this plant (Mandal and Chatterjee, 1987; Chakravarty et al.,
1991, 1994; Mandal et al., 1992; Chatterjee and Pakrashi,
1995; Pant et al., 2000). The wide-range biological activities
of S. chirayita are attributed to the presence of a diverse
group of pharmacologically bioactive compounds belonging to
different classes such as xanthones and their derivatives, lignans,
alkaloids, flavonoids, terpenoids, iridoids, secoiridoids, and other
compounds such as chiratin, ophelicacid, palmitic acid, oleic
acid, and stearic acid (Pant et al., 2000; Patil et al., 2013).
The first isolated dimeric xanthone was chiratanin present in
different parts of S. chirayita. The pharmacological efficacy
of S. chirayita has been partly attributed to the biological
activity of major phytoconstituents including amarogentin,
swertiamarin, mangiferin, swerchirin, sweroside, amaroswerin,
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TABLE 3 | Antioxidant potential of different solvent extracts of S. chirayita
Plant part tested aExtracting solvent Test system Control used and result Toxicity test References
Whole plant 70% EtOH In vitro BHT and Vitamin C None Chen et al., 2011
IC50 = 267.80µg/mL (DPPH)
IC50 = 1.502 ± 0.200µg/mL (β-carotene)
IC50 = 6.50µg/mL (ABTS)
Whole plant 70% EtOH In vivo NA Cytotoxicity test-negative Chen et al., 2011
Whole plant MeOH In vitro BHT None Sharma et al., 2013b
EC50 = 27.70µg/ml (DPPH)
Whole plant MeOH In vitro BHA None Ahirwal et al., 2014
IC50 = 222.74µg/mL (DPPH)
Whole plant Water In vitro Gallic acid None Kumar et al., 2011
EC50 = 315.83µg/mL (DPPH)
Leaves Water In vitro BHA; BHT None Ghosh et al., 2012
IC50 = 86µg/mL (DPPH)
900 ± 11(4min) and 2070 ± 110 (30min)
µM Fe (II)/g sample DW (FRAP)
Whole plant 12% EtOH In vitro Ascorbic acid None Phoboo et al., 2013
IC50 = 156.62µg/mL (DPPH)
Whole plant In vitro Gallic acid None Kshirsagar et al., 2015
MeOH IC50 = 551.26µg/mL (DPPH)
EtOH IC50 = 557.61µg/mL (DPPH)
ACE IC50 = 551.96µg/mL (DPPH)
Water IC50 = 559.05µg/mL (DPPH)
ABTS, 2,2-azino-bis (3-ethylebenzthiazoline-6-sulphonicacid); BHA, Butylated hydroxy anisole; BHT, Butylated hydroxytoluene; DPPH, 2,2-Diphenyl-1-picrylhdrazyl; DW, Dry weight;
FRAP, Ferric Reducing Antioxidant Power
aExtracting solvent: ACE, acetone; EtOH, ethanol; MeOH, methanol
and gentiopicrin (Figure 3). Amarogentin is reported to be anti-
diabetic (Phoboo et al., 2013), anticancerous (Saha et al., 2006; Pal
et al., 2012), and antileishmanial (Ray et al., 1996; Medda et al.,
1999), whereas swertiamarin has been tested for its anti-hepatitis
(Wang et al., 2001), anticancer (Kavimani andManisenthlkumar,
2000), anti-arthritic activities (Saravanan et al., 2014). It has
been shown to exhibit anti-diabetic (Vaidya et al., 2013)
properties. Mangiferin is also reported to have anti-diabetic,
antiatherosclerotic (Pardo-Andreu et al., 2008), anticancer, anti-
HIV (Guha et al., 1996), antiparkinson (Kavitha et al., 2013),
and chemopreventive (Yoshimi et al., 2001) activities. Swerchirin
is known to be antimalarial, hypoglycemic (Bajpai et al.,
1991; Saxena et al., 1996), hepatoprotective, pro-heamatopoietic
(Ya et al., 1999), with blood glucose lowering activity (Sekar
et al., 1987; Saxena et al., 1991) and weak chemo preventive
pharmacological effects (Hirakawa et al., 2005). Swerchirin
at different concentrations (1, 10, and 100µM) significantly
enhanced glucose stimulated insulin release from isolated islets
(Saxena et al., 1993). Sweroside is reported to be antibacterial
(Siler et al., 2010), hepatoprotective (Liu et al., 1994; Luo et al.,
2009), preventative in treatment for hyperpigmentation (Jeong
et al., 2015), and is also suggested as a promising osteoporosis
therapeutic natural product (Sun et al., 2013). Amaroswerin is
known for its gastroprotective effects of the bitter principles
(Niiho et al., 2006). Table 4 provides a summary focusing on the
biological activity of the phytochemicals present in S. chirayita.
SAFETY EVALUATION
Concerns regarding safety of conventional drugs are vital issues
of pharmaceutical industries. Studies have indicated that some
commonly used medicinal plants may be mutagenic or cytotoxic
especially over a long period of use (Verschaeve and Van Staden,
2008). There is increasing evidence on the toxicity of crude
extracts and isolated compounds from different plant species
(Koorbanally et al., 2006). However, despite its long history of
use in traditional medicine, there is still a lack of scientific
information concerning the safety evaluation of S. chirayita. It
can be traced through the medicinal history as a nontoxic and
safe ethnomedicinal herb and has been mentioned in medical
papyri to expel fever, relieve headache, inflammation, and to
stimulate the central nervous system. S. chirayita extracts, did not
cause obvious toxic effects in mice as there were no significant
differences in body weight and body temperature between the
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FIGURE 3 | Chemical structures of important phytoconstituents found in Swertia chirayita.
treated and control groups (Alam et al., 2011; Das et al., 2012).
A clinical study by Medda et al. (1999) concluded that S.
chirayita revealed no evidence of toxicity in both liposomal and
niosomal forms. Furthermore, stringent efforts are required to
further delineate the well-documented toxicological properties
involving toxicity and mutagenic tests to evaluate the safety
of this plant. Nevertheless, rigorous clinical studies involving
different mechanisms are still needed to confirm the safety of S.
chirayita in traditional medicine so that it can be used safely and
effectively. Despite the fact that the benefits of medicinal plants
is globally acknowledged, the need for better insight on the safety
evaluation remains essential, so as to differentiate between toxic
effects and pharmacological importance of plant extracts (Aremu
and Van Staden, 2013).
SWERTIA CHIRAYITA CONSERVATION
Destruction of plant resources is a normal occurrence. The
current speed of extinction through human interferences is
estimated to be approximately 100–1000 times faster than
the natural speed of extinction (Chapin et al., 2000). Due
to developmental activities in the Himalayan region, wild
populations of many medicinal plants, including S. chirayita are
reduced to the verge of extinction. S. chirayita is traded and used
mostly as a traditional drug. Due to its multiple uses the demand
is on the rise by both national and international trading leading to
increasing over harvesting of wild populations. This has resulted
in drastic reductions of its populations. Lack of comprehensive
data on annual harvested and traded plants of S. chirayita is
also a major concern. According to the International Union of
Conservation of Nature (IUCN) criteria, S. chirayita conservation
status has been categorized as “critically endangered” (Joshi
and Dhawan, 2005). S. chirayita is among the 32 most highly
prioritizedmedicinal plants of India as identified by The National
Medicinal Plant Board, Government of India (http://www.nmpb.
nic.in).
The implication of losing this plant species due to extinction
lies not only in the loss of genes useful for plant development or in
the biosynthesis of new compounds but also the loss of potentially
novel compounds of pharmaceutical or nutraceutical benefit. In
order tomeet the escalating demand in national and international
trade markets of raw plants, cultivation must be escalated.
There are limitations in the use of seed propagation, due to
low viability, and low germination percentages (Badola and Pal,
2002; Chandra et al., 2012). Biotechnology offers new means
of improving biodiversity and biotechnological approaches such
as micropropagation techniques (Figure 1E) has received more
attention and may play a vital role in the establishment
of genetically uniform plants for the Swertia industry. It is
believed that the development of efficient micropropagation
protocols, can guarantee an adequate supply of S. chirayita
plants (devoid of environmental-imposed constraints) with
subsequent reduction in uncontrolled harvesting pressure on
wild populations. Several studies reported on micropropagation,
somatic embryogenesis and acclimatization procedures with the
capacity to produce many uniform S. chirayita clones throughout
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TABLE 4 | Important bioactive compounds isolated from Swertia chirayita.
Phytochemical Biological activity References
Amarogentin Antileishmanial Ray et al., 1996; Medda
et al., 1999
Topoisomerase inhibitor Ray et al., 1996
Anticancer Saha et al., 2006; Pal et al.,
2012
Anti-diabetic Phoboo et al., 2013
Gastroprotective Niiho et al., 2006
Swertiamarin CNS depressant Bhattacharya et al., 1976
Anticholinergic Suparna et al., 1998
Anticancer Kavimani and
Manisenthlkumar, 2000
Anti-hepatitis Wang et al., 2001
Antibacterial Kumarasamy et al., 2003
Cardio-protective,
anti-atherosclerotic
Vaidya et al., 2009
anti-diabetic Vaidya et al., 2013
Anti-arthritic Saravanan et al., 2014
Mangiferin Antiviral Zheng and Lu, 1990
Immunomodulatory,
antitumor, anti-HIV
Guha et al., 1996
Antioxidant Sanchez et al., 2000
Chemopreventive Yoshimi et al., 2001
Antiinflammatory Kumar et al., 2003
Hypoglycemic Muruganandan et al., 2005
Anti-diabetic,
Antiatherosclerotic
Pardo-Andreu et al., 2008
Antiparkinson Kavitha et al., 2013
Swerchirin Hypoglycemic Bajpai et al., 1991; Saxena
et al., 1996
Hepatoprotective,
pro-heamatopoietic
Ya et al., 1999
Blood glucose lowering
activity
Sekar et al., 1987; Saxena
et al., 1993
Chemopreventive Hirakawa et al., 2005
Sweroside Antibacterial Siler et al., 2010
Hepatoprotective Liu et al., 1994; Luo et al.,
2009
Hyperpigmentation Jeong et al., 2015
Osteoporosis Sun et al., 2013
Amaroswerin Gastroprotective Niiho et al., 2006
Gentianine Antipsychotic Bhattacharya et al., 1974
Antimalarial Natarajan et al., 1974
Oleanolic acid Antimicrobial Jesus et al., 2015
Antitumor Soica et al., 2014
Antiinflamatory,
antioxidant
Liu, 1995
Ursolic acid Antimicrobial Jesus et al., 2015
(Continued)
TABLE 4 | Continued
Phytochemical Biological activity References
Antitumor Bonaccorsi et al., 2008;
Soica et al., 2014
Swertanone Antiinflammatory Kumar et al., 2003;
Tabassum et al., 2012
Syringaresinol Hepatoprotective Chakravarty et al., 1994
Bellidifolin Hypoglycemic Basnet et al., 1995
Isobellidifolin Hypoglycemic Basnet et al., 1995
1-Hydroxy-3,5,8-
trimethoxyxanthone
Antimalarial Mandal and Chatterjee,
1994
1-Hydroxy-3,7,8-
trimethoxyxanthone
Spasmogenic agent Ateufack et al., 2007
Antiulcerogenic Ateufack et al., 2014
1,5,8-trihydroxy-3-
methoxyxanthone
Blood sugar lowering Ghosal et al., 1973
β-Amyrin Anti-inflammatory Holanda et al., 2008
Antimicrobial, antifungal Vázquez et al., 2012
Chiratol Anti-inflammatory Banerjee et al., 2000
the year (Kumar and Chandra, 2013, 2014; Kumar et al.,
2014). As shown in Table 5, micropropagation protocols have
successfully been established for S. chirayita using different
explants.
Synthetic seed technology is also an applied application of
modern plant biotechnology which offers tremendous potential
for easy handling, micropropagation and plant germplasm
conservation through cryopreservation (Ara et al., 2000; Sharma
et al., 2013a; Perveen and Anis, 2014; Gantait et al., 2015).
Successful implementation of synthetic seed technology for
mass propagation and short-term storage of genetically uniform
clones require manipulation of in vitro tissue culture systems
that are able to transform into complete plantlets (Ara et al.,
2000). Recently, Kumar et al. (2014) reported on synthetic seed
production and plant regeneration of S. chirayita from somatic
embryos. However, further studies are required to improve
technology so that it can be used on a commercial scale.
Many plant secondary metabolites accumulate in roots (Flores
et al., 1999) but harvesting of these organs is destructive.
Therefore, in the recent past Agrobacterium rhizogenes induced
hairy root technology has received attention and engaged a
new platform of applied research in generating pharmaceutical
lead compounds. The large scaling-up of hairy root cultures
is of importance for biotechnological applications (Guillon
et al., 2006). Attempts have been made to standardize
A. rhizogenes transformed root cultures for production of
active secondary metabolites under in vitro conditions of
S. chirayita (Keil et al., 2000). For commercialization of S.
chirayita adventitious roots and to elucidate the feasibility
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TABLE 5 | Micropropagation data for Swertia chirayita.
Tissue culture Study Explant type Optimum concentrations Major observations References
Regeneration Seeds 3.0µM BA Adventitious shoot regeneration from root
explants
Wawrosch et al., 1999
Micropropagation In vivo axillary bud/
shoot apices
0.5mg/l BA + 1.0mg/l GA3 Methods and compositions for rapid
in vitro propagation
Ahuja et al., 2003
Axillary multiplication Seedling-derived
nodal explants
4.0µM BA + 1.5µM 2iP Improved shoot proliferation Joshi and Dhawan, 2007
Regeneration In vivo stem with
node
0.44µM BA + 4.65µM KN Improved regeneration from the nodal
explants
Chaudhuri et al., 2007
Direct shoot
multiplication
In vitro leaves 2.22µM BA + 11.6µM KN + 0.5µM NAA Improved protocol for propagation Chaudhuri et al., 2008
Regeneration Seeds 2.22µM BA + 2.22µM KN + 0.54µM
NAA
Regeneration from immature seed culture Chaudhuri et al., 2009
Direct shoot
regeneration
In vivo leaves 13.32µM BA + 0.54µM NAA In vitro shoot regeneration Wang et al., 2009
Micropropagation In vitro shoot tip 1.0mg/l BA + 0.1mg/l KN Improved shoot proliferation Balaraju et al., 2009a
In vitro regeneration Node 2mg/l BA Rapid in vitro propagation system Koul et al., 2009
Shoot Organogenesis In vitro root 4.44µM BA + 1.07µM NAA Improved protocol for plant regeneration Pant et al., 2010
Somatic embryogenesis In vivo leaves 1.0mg/l 2,4-D and 0.5mg/l 2,4-D +
0.5mg/l BA
Rapid system for micropropagation Balaraju et al., 2011
Callus culture In vitro root 13.32µM BA + 0.90µM 2,4-D Plant regeneration via indirect
organogenesis
Pant et al., 2012
Efficient Regeneration In vivo shoot tip 0.5mg/l BA + 1.0mg/l GA3 An efficient shoot proliferation Kumar and Chandra,
2013
In vitro flower production Axillary bud 1.0mg/l BA + 70mg/l Adenine sulfate In vitro flowering and effective protocol for
regeneration
Sharma et al., 2014
Somatic embryogenesis In vivo leaves 0.5mg/l 2,4-D + 0.5mg/l KN An efficient protocol for plant regeneration
through somatic embryogenesis
Kumar and Chandra,
2014
Direct and Indirect
regeneration
In vivo leaves 1.0mg/l BA + 100mg/l Adenine sulfate +
0.1mg/l IAA
An efficient protocol of plant regeneration
through direct and indirect organogenesis
Kumar et al., 2014
2,4-D, 2,4-Dicholorophenoxyacetic acid; BA, 6-benzyl-adenine; GA3, Gibberellic acid; IAA, Indole-3-acetic acid; KN, Kinetin; NAA, Naphthalene Acetic Acid.
for commercial application, hairy root technology is required
along with various factors affecting the production of root
biomass and bioactive compounds. Overall, micropropagation
which is conducted under a controlled environment will
help to prevent the current plant biodiversity conservation
problems arising from over harvesting practices of wild
populations and can profoundly improve the quality of
bioactive secondary metabolites of this age old medicinal plant
S. chirayita.
CONCLUSIONS AND FUTURE
PERSPECTIVES
S. chirayita offers many promising prospects for both traditional
and modern medicine. S. chirayita is apparently a potential
herbal therapy for many ailments. This review summarized the
existing ethnobotanical uses, phytochemistry, pharmacological
activities, safety evaluation, and conservation status on
S. chirayita.
So far no serious side effects or toxicity of S. chirayita have
been reported, but further toxicological studies are still needed
to confirm the safety of S. chirayita in humans. Efforts are
required for further studies, especially evaluating its biological
activities in vivo and toxicological and mutagenic properties in
order to better validate the safety of these different plant-derives
compounds. In all probability there is a need for clinical trials
to establish the efficacy of using S. chirayita in medicine. Due to
its multiple uses the demand in both national and international
markets is constantly on the rise. Overexploitation combined
with habitat destruction has resulted in the drastic reduction of its
population. For the successful commercialization of this critically
endangered medicinal plant any proposed research must be
viewed in a wider context that includes conservation practices
and sustainable supply of raw plants. This will require innovative
tools, which utilize biotechnological interventions, including
micropropagation, cryopreservation, and bioreactors for the
conservation, as well as for raising commercial production. In
synthetic seed technology more detailed research is required
mainly for improvement in germination frequency of synthetic
seeds and subsequent plantlet growth in soil so that it can be
used on a commercial scale. Additionally, in the near future,
hairy root technology can be used as a model system and
will also provide plant biotechnologists with powerful tools to
improve the valuable phytochemicals of S. chirayita. Although
efficient micropropagation protocols have been established,
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further studies focusing on seed biology and ways of improving
bioactive secondary metabolites in cultivated S. chirayita would
be beneficial for their commercialization. Quality control
protocols to prevent misidentification and possible adulteration
of S. chirayita are also needed. In summary, S. chirayita have
been studied extensively in terms of taxonomy, ethnobotany,
phytochemistry, biological activities, and conservation. However,
new findings may increase the present therapeutic importance of
S. chirayita and promote their future use in modern medicine,
while novel biotechnological approaches are required for further
conservation.
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